|
1
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM
and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mahar AL, Compton C, Halabi S, Hess KR,
Weiser MR and Groome PA: Personalizing prognosis in colorectal
cancer: A systematic review of the quality and nature of clinical
prognostic tools for survival outcomes. J Surg Oncol. 116:969–982.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fakih MG: Metastatic colorectal cancer:
Current state and future directions. J Clin Oncol. 33:1809–1824.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martini G, Troiani T, Cardone C, Vitiello
P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo
F, Raucci A, et al: Present and future of metastatic colorectal
cancer treatment: A review of new candidate targets. World J
Gastroenterol. 23:4675–4688. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dyer AH, Vahdatpour C, Sanfeliu A and
Tropea D: The role of insulin-like growth factor 1 (IGF-1) in brain
development, maturation and neuroplasticity. Neuroscience.
325:89–99. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lin Y, Liu H, Waraky A, Haglund F, Agarwal
P, Jernberg-Wiklund H, Warsito D and Larsson O: SUMO-modified
insulin-like growth factor 1 receptor (IGF-1R) increases cell cycle
progression and cell proliferation. J Cell Physiol. 232:2722–2730.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Heidegger I, Kern J, Ofer P, Klocker H and
Massoner P: Oncogenic functions of IGF1R and INSR in prostate
cancer include enhanced tumor growth, cell migration and
angiogenesis. Oncotarget. 5:2723–2735. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Riedemann J and Macaulay VM: IGF1R
signalling and its inhibition. Endocr Relat Cancer. 13 (Suppl
1):S33–S43. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodrigues Alves APN, Fernandes JC,
Fenerich BA, Coelho-Silva JL, Scheucher PS, Simões BP, Rego EM,
Ridley AJ, Machado-Neto JA and Traina F: IGF1R/IRS1 targeting has
cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in
acute lymphoblastic leukemia cells. Cancer Lett. 456:59–68. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zorea J, Prasad M, Cohen L, Li N, Schefzik
R, Ghosh S, Rotblat B, Brors B and Elkabets M: IGF1R upregulation
confers resistance to isoform-specific inhibitors of PI3K in
PIK3CA-driven ovarian cancer. Cell Death Dis. 9:9442018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Warsito D, Lin Y, Gnirck AC, Sehat B and
Larsson O: Nuclearly translocated insulin-like growth factor 1
receptor phosphorylates histone H3 at tyrosine 41 and induces SNAI2
expression via Brg1 chromatin remodeling protein. Oncotarget.
7:42288–42302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Packham S, Warsito D, Lin Y, Sadi S,
Karlsson R, Sehat B and Larsson O: Nuclear translocation of IGF-1R
via p150(Glued) and an importin-β/RanBP2-dependent pathway in
cancer cells. Oncogene. 34:2227–2238. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Warsito D, Sjostrom S, Andersson S,
Larsson O and Sehat B: Nuclear IGF1R is a transcriptional
co-activator of LEF1/TCF. EMBO Rep. 13:244–250. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sehat B, Tofigh A, Lin Y, Trocmé E,
Liljedahl U, Lagergren J and Larsson O: SUMOylation mediates the
nuclear translocation and signaling of the IGF-1 receptor. Sci
Signal. 3:ra102010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aleksic T, Verrill C, Bryant RJ, Han C,
Worrall AR, Brureau L, Larré S, Higgins GS, Fazal F, Sabbagh A, et
al: IGF-1R associates with adverse outcomes after radical
radiotherapy for prostate cancer. Br J Cancer. 117:1600–1606. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang Y, Yuan JL, Zhang YT, Ma JJ, Xu P,
Shi CH, Zhang W, Li YM, Fu Q, Zhu GF, et al: Inhibition of both
EGFR and IGF1R sensitized prostate cancer cells to radiation by
synergistic suppression of DNA homologous recombination repair.
PLoS One. 8:e687842013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guerard M, Robin T, Perron P, Hatat AS,
David-Boudet L, Vanwonterghem L, Busser B, Coll JL, Lantuejoul S,
Eymin B, et al: Nuclear translocation of IGF1R by intracellular
amphiregulin contributes to the resistance of lung tumour cells to
EGFR-TKI. Cancer Lett. 420:146–155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Her J and Bunting SF: How cells ensure
correct repair of DNA double-strand breaks. J Biol Chem.
293:10502–10511. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wright WD, Shah SS and Heyer WD:
Homologous recombination and the repair of DNA double-strand
breaks. J Biol Chem. 293:10524–10535. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang HHY, Pannunzio NR, Adachi N and
Lieber MR: Non-homologous DNA end joining and alternative pathways
to double-strand break repair. Nat Rev Mol Cell Biol. 18:495–506.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Escribano-Diaz C, Orthwein A,
Fradet-Turcotte A, Xing M, Young JT, Tkáč J, Cook MA, Rosebrock AP,
Munro M, Canny MD, et al: A cell cycle-dependent regulatory circuit
composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway
choice. Mol Cell. 49:872–883. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chapman JR, Barral P, Vannier JB, Borel V,
Steger M, Tomas-Loba A, Sartori AA, Adams IR, Batista FD and
Boulton SJ: RIF1 is essential for 53BP1-dependent nonhomologous end
joining and suppression of DNA double-strand break resection. Mol
Cell. 49:858–871. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salvador Moreno N, Liu J, Haas KM, Parker
LL, Chakraborty C, Kron SJ, Hodges K, Miller LD, Langefeld C,
Robinson PJ, et al: The nuclear structural protein NuMA is a
negative regulator of 53BP1 in DNA double-strand break repair.
Nucleic Acids Res. 47:2703–2715. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chitnis MM, Lodhia KA, Aleksic T, Gao S,
Protheroe AS and Macaulay VM: IGF-1R inhibition enhances
radiosensitivity and delays double-strand break repair by both
non-homologous end-joining and homologous recombination. Oncogene.
33:5262–5273. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Waraky A, Lin Y, Warsito D, Haglund F,
Aleem E and Larsson O: Nuclear insulin-like growth factor 1
receptor phosphorylates proliferating cell nuclear antigen and
rescues stalled replication forks after DNA damage. J Biol Chem.
292:18227–18239. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Doncheva NT, Morris JH, Gorodkin J and
Jensen LJ: Cytoscape StringApp: Network analysis and visualization
of proteomics data. J Proteome Res. 18:623–632. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bindea G, Mlecnik B, Hackl H, Charoentong
P, Tosolini M, Kirilovsky A, Fridman WH, Pagès F, Trajanoski Z and
Galon J: ClueGO: A Cytoscape plug-in to decipher functionally
grouped gene ontology and pathway annotation networks.
Bioinformatics. 25:1091–1093. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Huang C, Yuan W, Lai C, Zhong S, Yang C,
Wang R, Mao L and Chen Z and Chen Z: EphA2-to-YAP pathway drives
gastric cancer growth and therapy resistance. Int J Cancer.
146:1937–1949. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
ten Have S, Boulon S, Ahmad Y and Lamond
AI: Mass spectrometry-based immuno-precipitation proteomics-the
user's guide. Proteomics. 11:1153–1159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kakarougkas A and Jeggo PA: DNA DSB repair
pathway choice: An orchestrated handover mechanism. Br J Radiol.
87:201306852014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu Y and Her C: Inhibition of
topoisomerase (DNA) I (TOP1): DNA damage repair and anticancer
therapy. Biomolecules. 5:1652–1670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rocha JC, Busatto FF, Guecheva TN and
Saffi J: Role of nucleotide excision repair proteins in response to
DNA damage induced by topoisomerase II inhibitors. Mutat Res Rev
Mutat Res. 768:68–77. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Lange T: Shelterin-mediated telomere
protection. Ann Rev Genet. 52:223–247. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maiato H and Pereira AJ: Cell division:
NuMA bears the load in the spindle. Curr Biol. 27:R765–R767. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gallini S, Carminati M, De Mattia F,
Pirovano L, Martini E, Oldani A, Asteriti IA, Guarguaglini G and
Mapelli M: NuMA phosphorylation by Aurora-A orchestrates spindle
orientation. Curr Biol. 26:458–469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kotak S and Gonczy P: Mechanisms of
spindle positioning: Cortical force generators in the limelight.
Curr Opin Cell Biol. 25:741–748. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Werner H, Sarfstein R and Bruchim I:
Investigational IGF1R inhibitors in early stage clinical trials for
cancer therapy. Expert Opin Investig Drugs. 28:1101–1112. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qu X, Wu Z, Dong W, Zhang T, Wang L, Pang
Z, Ma W and Du J: Update of IGF-1 receptor inhibitor (ganitumab,
dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on
cancer therapy. Oncotarget. 8:29501–29518. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yee D: Anti-insulin-like growth factor
therapy in breast cancer. J Mol Endocrinol. 61:T61–T68. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aleksic T, Gray N, Wu X, Rieunier G, Osher
E, Mills J, Verrill C, Bryant RJ, Han C, Hutchinson K, et al:
Nuclear IGF1R interacts with regulatory regions of chromatin to
promote RNA Polymerase II recruitment and gene expression
associated with advanced tumor stage. Cancer Res. 78:3497–3509.
2018.PubMed/NCBI
|
|
42
|
Solomon-Zemler R, Pozniak Y, Geiger T and
Werner H: Identification of nucleolar protein NOM1 as a novel
nuclear IGF1R-interacting protein. Mol Genet Metab. 126:259–265.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Solomon-Zemler R, Sarfstein R and Werner
H: Nuclear insulin-like growth factor-1 receptor (IGF1R) displays
proliferative and regulatory activities in non-malignant cells.
PLoS One. 12:e01851642017. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wickramasinghe VO and Venkitaraman AR: RNA
processing and genome stability: Cause and consequence. Mol Cell.
61:496–505. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Radulescu AE and Cleveland DW: NuMA after
30 years: The matrix revisited. Trends Cell Biol. 20:214–222. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wu J, Xu Z, He D and Lu G: Identification
and characterization of novel NuMA isoforms. Biochem Biophys Res
Commun. 454:387–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Panier S and Boulton SJ: Double-strand
break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol.
15:7–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Serra-Marques A, Houtekamer R, Hintzen D,
Canty JT, Yildiz A and Dumont S: The mitotic protein NuMA plays a
spindle-independent role in nuclear formation and mechanics. J Cell
Biol. 219:e2020042022020. View Article : Google Scholar : PubMed/NCBI
|
